Small Volume Injectables Nalmefene Hydrochloride Injection
Obtained the FDA approval letter on November 15, 2023, marking its approved launch in the United States. FDA-approved indications: complete or partial reversal of opioid effects, including respiratory depression induced by natural or synthetic opioids, and the treatment of known or suspected opioid overdose.
Chengdu Shuode Pharmaceutical Co., Ltd.
